Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 26 MAY 2026

India’s Ozempic Moment

Remfry & Sagar
Remfry & Sagar
Contributor

Remfry & Sagar

Established in 1827, Remfry & Sagar has pioneered IP law in India. The firm’s depth of experience...

View firm profile
Explore more from Remfry & Sagar

Semaglutide, sold under the blockbuster brands Ozempic and Wegovy, has become one of the most talked-about drugs in recent memory. It belongs to a class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar.

IndiaIntellectual Property
Pankaj Soni
Pankaj Soni
Bisman Kaur
Bisman Kaur

Semaglutide, sold under the blockbuster brands Ozempic and Wegovy, has become one of the most talked-about drugs in recent memory. It belongs to a class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar. Originally developed to treat Type 2 diabetes, its dramatic weight-loss effects have made it a global commercial phenomenon. In India, the drug is now at the centre of a convergence of IP battles, a generic market explosion, and a regulatory crackdown, all unfolding within the span of a few months. This piece surveys the landscape.

The Patent Battle: Novo Nordisk v. Dr. Reddy’s Laboratories

Novo Nordisk A/S v. Dr. Reddy's Laboratories Ltd. & Anr., Delhi High Court, ruling of March 9, 2026 (2026:DHC:1911-DB)

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Copy, Right? ANI Media Pvt. Ltd. v. Open AI OpCo LLC

When an artificial intelligence system is trained on copyrighted news content, and later answers a user’s question using what it learned, has the law been broken? On 24th July 2026, the Delhi High Court answered that question, at least for now. In ANI Media Pvt. Ltd. v. Open AI OpCo LLC, Justice Amit Bansal declined to grant an interim injunction against OpenAI, holding, on a prima facie, interim stage view, that the company’s use of ANI’s news content to train its large language models (“LLMs”) falls within the fair dealing exception under Section 52(1)(a) of the Copyright Act, 1957
IndiaIntellectual Property
S.S. Rana & Co.
S.S. Rana & Co.
Article

AI Training Data, Copyright Risk And Commercial Liability: What Businesses Need To Know

On 8 October 2026, USA Today Co. and its affiliated newspaper companies, which publish 19 titles including USA Today, the Detroit Free Press and The Arizona Republic, sued seven OpenAI entities in the US District Court for the Southern District of New York. The complaint alleges that OpenAI copied their journalism to train its models, stripped identifying information from it, and now uses those models to give ChatGPT users summaries that substitute for the original reporting. The publishers seek more than USD 250 million in damages, an injunction and an order for the destruction of models and training sets containing their content.
IndiaIntellectual Property
Legitpro Law
Legitpro Law